Home › Funds › Lion Point Capital, LP › ARQT
Lion Point Capital, LP position in ARQT
ARCUTIS BIOTHERAPEUTICS INC · Health Care
Lion Point Capital, LP reported holding 5,250 shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$138K, representing 0.66% of its reported portfolio and ranking #34 among its reported holdings. Lion Point Capital, LP has disclosed ARQT holdings in 8 of the last 8 reported quarters, going back to Q3 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Lion Point Capital, LP's ARQT position evolved
Lion Point Capital, LP first disclosed a stake in ARQT in Q3 2024 at 35,100 shares (US$326K). The position peaked in Q1 2025 at 46,300 shares, worth US$724K. Across 8 filings, Lion Point Capital, LP increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 5,250 shares valued at US$138K. Notable position changes include a 32% increase in Q4 2024 (shares rose 12% over the following quarter), a 85% trim in Q4 2025 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 35.10K | $326.43K | New |
| Q4 2024 | 46.30K | $644.96K | Add |
| Q1 2025 | 46.30K | $724.13K | Hold |
| Q2 2025 | 46.30K | $649.13K | Hold |
| Q3 2025 | 35.30K | $665.40K | Reduce |
| Q4 2025 | 5.25K | $152.46K | Reduce |
| Q1 2026 | 5.25K | $123.69K | Hold |
| Q2 2026 | 5.25K | $137.66K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARQT and 13F data
ARQT (ARCUTIS BIOTHERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in ARQT — the largest reported positions include MONTANOVA CAPITAL, LLC (US$326.1M), Frazier Life Sciences Management, L.P. (US$258.9M), Rubric Capital Management LP (US$216.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARQT
- MONTANOVA CAPITAL, LLC 12.44M sh · $326.10M · Q2 2026
- Frazier Life Sciences Management, L.P. 9.87M sh · $258.91M · Q2 2026
- Rubric Capital Management LP 8.27M sh · $216.88M · Q2 2026
- ORBIMED ADVISORS LLC 2.04M sh · $53.54M · Q2 2026
- OBERWEIS ASSET MANAGEMENT INC/ 1.37M sh · $36.00M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.27M sh · $33.18M · Q2 2026
- Jones Hill Capital LP 1.09M sh · $28.57M · Q2 2026
- FISHMAN JAY A LTD/MI 595.00K sh · $15.60M · Q2 2026
More on Lion Point Capital, LP
FAQ
How long has Lion Point Capital, LP held ARQT?
Lion Point Capital, LP has disclosed ARQT holdings in 8 of the last 8 reported quarters, going back to Q3 2024.
What is Lion Point Capital, LP's current position in ARQT?
As of Q2 2026, Lion Point Capital, LP holds 5.25K shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC), valued at $137.66K, representing 0.66% of its reported portfolio and ranking #34.
Has Lion Point Capital, LP been buying or selling ARQT?
In the latest 13F filing (Q2 2026), Lion Point Capital, LP held unchanged its position in ARQT. The position peaked in Q1 2025 at 46.30K shares.
Which other funds hold ARQT?
Other major institutional holders of ARQT include MONTANOVA CAPITAL, LLC, Frazier Life Sciences Management, L.P., Rubric Capital Management LP, among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.